Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0000173
UniProt IDQ7L266
Primary gene name(s)ASRGL1
Synonym gene name(s)ALP, CRASH
Protein nameIsoaspartyl peptidase/L-asparaginase
Protein functionHas both L-asparaginase and beta-aspartyl peptidase activity. May be involved in the production of L-aspartate, which can act as an excitatory neurotransmitter in some brain regions. Is highly active with L-Asp beta-methyl ester. Besides, has catalytic activity toward beta-aspartyl dipeptides and their methyl esters, including beta-L-Asp-L-Phe, beta-L-Asp-L-Phe methyl ester, aspartame, beta-L-Asp-L-Ala, beta-L-Asp-L-Leu and beta-L-Asp-L-Lys. Does not have aspartylglucosaminidase activity and is inactive toward GlcNAc-L-Asn. Likewise, has no activity toward glutamine. {ECO:0000269|PubMed:19839645}.
Subcellular locationCytoplasm {ECO:0000269|PubMed:11984834}. Note=Midpiece of sperm tail.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: Q7L266
Gene Ontology
(Biological Process)
Complete annatation
asparagine catabolic process via L-aspartate [GO:0033345];
L-phenylalanine catabolic process [GO:0006559]
Gene Ontology
(Molecular Function)
Complete annatation
asparaginase activity [GO:0004067];
beta-aspartyl-peptidase activity [GO:0008798]
Gene Ontology
(Cellular Component)
Complete annatation
cytoplasm [GO:0005737];
cytosol [GO:0005829];
nucleus [GO:0005634]
Protein-protein interaction123142
Phylogenetic treeQ7L266
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
Brass et al., Science, 2008
Smith et al., J. Immunol, 2010
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model

DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.4639216873998920.2757851439478240.391102153705458
AZA vs. DISU-0.2862039054721180.6122680247649510.957895177103442
AZA vs. IL70.05236542226929020.9209818307766860.999311006273513
AZA vs. SAHA-0.1313199772144940.8024873728581340.948611563555796
DISU vs. CD3-0.7663344770625170.111674746312570.203307382356966
DISU vs. IL70.3309336785200660.5623969182278860.858352972472762
DISU vs. SAHAunknownunknownunknown
DMSO vs. AZA-0.01681891228096020.9710599300206741
DMSO vs. CD3-0.5003039683716310.1638995683338110.254682516446505
DMSO vs. DISUunknownunknownunknown
DMSO vs. IL70.07438950094103440.8745780098403720.972698356853146
DMSO vs. SAHAunknownunknownunknown
HIV vs. Mock in Activation-0.1322396416180060.8437780933033830.999983755607037
HIV vs. Mock in Latencyunknownunknownunknown
IL7 vs. CD3-0.4066061223098770.3637366834609470.501197827023207
SAHA vs. CD3-0.6211328686746560.1544006881567060.246337329219558
SAHA vs. IL7-0.1888417037629590.7232608502273230.873105984344587
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) FALSE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK 0.396043 0.0590778
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.962 1.457 1.781 2.07 2.21
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB00128 L-Aspartic Acid approved, nutraceutical unknown unknown
DB00174 L-Asparagine approved, nutraceutical unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
3TKJ X-ray 2.3Å A/B=2-308.
4ET0 X-ray 3.3Å A/B=2-308.
4O0C X-ray 1.5Å A/B=1-308.
4O0D X-ray 1.9Å A/B=1-308.
4O0E X-ray 1.7Å A/B=1-308.
4O0F X-ray 1.9Å A/B=1-308.
4O0G X-ray 2.1Å A/B=1-308.
4O0H X-ray 1.9Å A/B=1-308.
4OSX X-ray 1.9Å A/B=1-308.
4OSY X-ray 1.9Å A/B=1-308.
4PVP X-ray 1.8Å A/B=1-308.
4PVQ X-ray 2.1Å A/B=1-308.
4PVR X-ray 1.7Å A/B=1-308.
4PVS X-ray 1.8Å A/B=1-308.
4ZM9 X-ray 2.5Å A/B/C/D=2-308.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Envelope transmembrane glycoprotein gp41 downregulates 23383108

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
not found